Leap Therapeutics (LPTX) Shares Down 6.1%
Leap Therapeutics Inc (NASDAQ:LPTX) shares traded down 6.1% during trading on Thursday . The stock traded as low as $1.81 and last traded at $1.85. 1,147,462 shares traded hands during mid-day trading, an increase of 56% from the average session volume of 737,549 shares. The stock had previously closed at $1.97.
A number of research analysts have commented on LPTX shares. Zacks Investment Research raised shares of Leap Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 16th. ValuEngine downgraded shares of Leap Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, January 4th. Finally, Raymond James cut their target price on shares of Leap Therapeutics from $13.00 to $8.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 19th.
The stock has a market cap of $41.90 million, a P/E ratio of -0.56 and a beta of 2.29.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC acquired a new stake in Leap Therapeutics during the 4th quarter valued at approximately $28,000. JPMorgan Chase & Co. acquired a new stake in Leap Therapeutics during the 3rd quarter valued at approximately $111,000. Renaissance Technologies LLC lifted its stake in Leap Therapeutics by 23.5% during the 3rd quarter. Renaissance Technologies LLC now owns 138,868 shares of the company’s stock valued at $1,082,000 after acquiring an additional 26,401 shares during the period. Vanguard Group Inc lifted its stake in Leap Therapeutics by 23.2% during the 3rd quarter. Vanguard Group Inc now owns 256,268 shares of the company’s stock valued at $1,997,000 after acquiring an additional 48,300 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Leap Therapeutics by 23.2% during the 3rd quarter. Vanguard Group Inc. now owns 256,268 shares of the company’s stock valued at $1,997,000 after acquiring an additional 48,300 shares during the period. Institutional investors and hedge funds own 9.08% of the company’s stock.
WARNING: This article was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://theolympiareport.com/2019/03/14/leap-therapeutics-lptx-shares-down-6-1.html.
About Leap Therapeutics (NASDAQ:LPTX)
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.